“Artificial intelligence”: Which services, which applications, which results and which development today in clinical research? Which impact on the quality of care? Which recommendations?

Vincent Diebolt, Isaac Azancot, François-Henri Boissel, Isabelle Adenot, Christine Balague, Philippe Barthélémy, Nacer Boubenna, Hélène Coulonjou, Xosé Fernandez, Enguerrand Habran, Françoise Lethiec, Juliette Longin, Anne Metzinger, Yvon Merlière, Emmanuel Pham, Pierre Philip, Thomas Roche, William Saurin, Anny Tirel, Emmanuelle Voisin, Thierry Marchal
Therapies. 2019-02-01; 74(1): 155-164
DOI: 10.1016/j.therap.2018.12.003

Lire sur PubMed

Diebolt V(1), Azancot I(2), Boissel FH(3); participants of Giens XXXIV round table ‘Hot topic N° 2’.

Collaborators: Adenot I(4), Balague C(5), Barthélémy P(6), Boubenna N(7), Coulonjou H(8), Fernandez X(9), Habran E(10), Lethiec F(11), Longin J(12), Metzinger A(13), Merlière Y(14), Pham E(15), Philip P(16), Roche T(17), Saurin W(18), Tirel A(19), Voisin E(20), Marchal T(21).

Author information:
(1)F-CRIN, pavillon Leriche, hôpital Purpan, place du Dr-Blayac, 31059 Toulouse
cedex 9, France. Electronic address: .
(2)Hôpital Lariboisière, AP-HP, 75475 Paris, France.
(3)Novadiscovery, 69009 Lyon, France.
(4)Haute autorité de santé, 93218 Saint-Denis la Plaine, France.
(5)Institut mines-telecom business school, 91011 Evry, France.
(6)Astrazeneca, 92400 Courbevoie, France.
(7)Inserm transfert, 75013 Paris, France.
(8)DRCI, AP-HP, 75475 Paris, France.
(9)Institut Curie, 75005 Paris, France.
(10)Fonds FHF recherche et innovation, 75993 Paris, France.
(11)Janssen Cilag, 92787 Issy-lès-Moulineaux, France.
(12)Merck santé, 69008 Lyon, France.
(13)Hospices civils de Lyon, HCL, DRCI, 69229 Lyon, France.
(14)CNAMTS, 75986 Paris, France.
(15)IPSEN, 91940 Les Ulis, France.
(16)Université de Bordeaux, CHU de Bordeaux, 33076 Bordeaux, France.
(17)Delsol avocats, 69001 Lyon, France.
(18)Dassault systèmes-3DS, 78946 Vélizy-Villacoublay, France.
(19)MSD, 92400 Courbevoie, France.
(20)Voisin consulting life science, 92100 Boulogne, France.
(21)ANSYS, université catholique de Louvain, 1348 Louvain la Neuve, Belgium.

Artificial intelligence (AI), beyond the concrete applications that have already
become part of our daily lives, makes it possible to process numerous and
heterogeneous data and knowledge, and to understand potentially complex and
abstract rules in a manner human intelligence can but without human intervention.
AI combines two properties, self-learning by the successive and repetitive
processing of data as well as the capacity to adapt, that is to say the
possibility for a scripted program to deal with multiple situations likely to
vary over time. Roundtable experts confirmed the potential contribution and
theoretical benefit of AI in clinical research and in improving the efficiency of
patient care. Experts also measured, as is the case for any new process that
people need to get accustomed to, its impact on practices and mindset. To
maximize the benefits of AI, four critical points have been identified. The
careful consideration of these four points conditions the technical integration
and the appropriation by all actors of the life science spectrum: researchers,
regulators, drug developers, care establishments, medical practitioners and,
above all, patients and the civil society. 1st critical point: produce tangible
demonstrations of the contributions of AI in clinical research by quantifying its
benefits. 2nd critical point: build trust to foster dissemination and
acceptability of AI in healthcare thanks to an adapted regulatory framework. 3rd
critical point: ensure the availability of technical skills, which implies an
investment in training, the attractiveness of the health sector relative to
tech-heavy sectors and the development of ergonomic data collection tools for all
health operators. 4th critical point: organize a system of governance for a
distributed and secure model at the national level to aggregate the information
and services existing at the local level. Thirty-seven concrete recommendations
have been formulated which should pave the way for a widespread adoption of AI in
clinical research. In this context, the French « Health data hub » initiative
constitutes an ideal opportunity.

Copyright © 2018. Published by Elsevier Masson SAS.


Auteurs Bordeaux Neurocampus